[Clinical investigation of XXXX with special reference to adjuvant chemotherapy].

@entity1 @entity3484 @entity2558 @entity1803 @entity5 @entity900 @entity150 @entity1698 @entity703
Clinical investigation of 93 @entity1 with histologically confirmed @entity703 were performed. These @entity1 consisted of 55 males and 38 females with a mean age of 64.8 years. There were 61 cases of @entity703 , 55 cases of @entity1698 and 23 with @entity5 of both sites. Thirty-four cases were associated with @entity150 and 41 of 82 @entity1 had @entity5 . The overall 5-year survival rate was 46.0%. 5-year survival of stages pTa, @entity2558 , pT2, @entity1803 , and pT4, was 93.3%, 71.8%, 37.5%, 30.4% and 10.5%, respectively. In this report, we evaluated various prognostic factors according to the survival rate. Sex, age, @entity5 localization, multiplicity, associated @entity150 and concomitance of CIS had no influence on survival. In the ABC analysis, the B group showed a tendency for a poor prognosis. However it may be explained from the fact that the B group contained more @entity1 at advanced stages than the other groups. @entity5 grade, @entity5 stage, pV factor and pL factor had a significant effect on survivals. But @entity5 grade, pV and pL factors were closely related to the @entity5 stage. Thus the stage was thought to be the most important factor in the prognosis of @entity3484 . Different surgical procedures and irradiation also did not affect the prognosis of the @entity1 with the same degree of invasion. Chemotherapy for all stages had no effect on survivals compared with non-chemotherapeutic group. However only for @entity1803 and higher stage cases, @entity900 -based chemotherapy improved the prognosis compared with @entity1 not given chemotherapy. In conclusion, chemotherapy containing @entity900 should be considered for treatment of high stage @entity3484 .
